Centers of Excellence Requirements

We welcome all qualifying physicians to submit their

application to become a leader in the AMD community.

Here are some of the highlighted criteria for an AMD COE with the MDA accreditation:

    • Completion and submission of the enrollment application.
    • Facility must operate business in compliance with all applicable federal and state licensure and regulatory requirements for the health and safety of patients.
    • Physicians treating AMD should be fellowship trained in retina, board certified in ophthalmology, and members in good standing of both American Society of Retina Specialists (ASRS) and American Academy of Ophthalmology (AAO).

-Facility must contain space for equipment appropriate to the services designated on the enrollment application, facilities for hand washing, adequate patient privacy accommodations, and the storage of both business records and current medical records.

– Facility should have all applicable diagnostic testing equipment available at the physical     site such as a spectral-domain or swept-source OCT device, fundus photography, autofluorescence, fluorescein angiogram, and diagnostic testing equipment.

– Testing equipment must be calibrated and maintained per equipment instructions and in compliance with applicable manufacturer’s suggested maintenance and calibration standards.

  • Each physician/facility should meet at least one of the following conditions:

– At a minimum, at least 30% of the practice should be AMD patients
– Participate in a multicenter study investigating a new treatment for AMD
– Lecture on AMD
– Author a paper or publication on AMD


  • A current complete catalog of diagnostic equipment, including diagnostic testing equipment serial and registration numbers, must be maintained at the physical site and available to the MDA upon request.
  • All physicians must stay current on all new technology while offering these new services to their patients.
  • All physicians agree to have available the following medications: bevacizumab (Avastin, Genentech); ranibizumab (Lucentis, Genentech); aflibercept (Eylea, Regeneron);brolucizumab-dbll (Beovu, Novartis), and any new anti-vascular endothelial growth factor (VEGF)/similar medication approved by the FDA and Medicare.
  • Have technical staff on duty with the appropriate credentials to perform diagnostic tests. The physical facility must be able to produce the applicable federal or state licenses or certifications of the individuals performing these services.
  • All applications and submitted documentation will be reviewed by the MDA’s medical director for final approval as an AMD Center of Excellence.